BACE-1

BACE-1

BACE-1 Informations sur la molécule

Molecule Name
Beta-secretase 1
Alias de la molécule
BACE1,ASP2,BACE,FLJ90568,HSPC104,KIAA1149,Memapsin-2,Beta-Secretase,β-secretase
Drug Development Progress
Nombre de médicaments cliniques3
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 3 Clinical
Alias de la cible
Beta-site amyloid precursor protein cleaving enzyme 1,KIAA1149,Asp 2,ASP2,Aspartyl protease 2,BACE,BACE1,Beta-Secretase 1,Membrane-Associated Aspartic Protease 2,Beta-Site APP-Cleaving Enzyme,Memapsin-2,Transmembrane Aspartic Proteinase Asp2,Beta-Site APP-Cleaving Enzyme 1,APP Beta-Secretase,EC 3.4.23.46,HSPC104,EC 3.4.23,Beta-Site APP Cleaving Enzyme 1,Beta-Site Amyloid Beta A4 Precursor Protein-Cleaving Enzyme,Beta-Secretase 1 Precursor Variant 1,EC:3.4.23.46
Contexte de la molécule
Beta-secretase 1 (BACE1) is also known as beta-site APP cleaving enzyme 1 (beta-site amyloid precursor protein cleaving enzyme 1), memapsin-2 (membrane-associated aspartic protease 2), and aspartyl protease 2 (ASP2), β-Secretase , and is a member of the peptidase A1 protein family, BACE1 is a type I  integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. BACE1 is an aspartic-acid protease important in the pathogenesis of Alzheimer's disease, and in the formation of myelin sheaths in peripheral nerve cells. The transmembrane protein contains two active site aspartate residues in its extracellular protein domain and may function as a dimer. This protease is responsible for the proteolytic processing of the amyloid precursor protein (APP). Generation of the 40 or 42 amino acid-long amyloid-β peptides that aggregate in the brain of Alzheimer's patients requires two sequential cleavages of the APP. Extracellular cleavage of APP by BACE creates a soluble extracellular fragment and a cell membrane-bound fragment referred to as C99. The elevation of BACE1 levels can be induced by amyloid plaques surrounding neurons at early stages of pathology before neuron death occurs, and may drive a positive-feedback loop in AD.

BACE-1 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
LanabecestatAZD-3293; LY-3314814Phase 3 ClinicalAstrazeneca Plc
Alzheimer Disease; Hepatic Insufficiency; Renal Insufficiency
Details
ElenbecestatE-2609Phase 3 ClinicalEisai Co Ltd
Alzheimer Disease
Details
TAK-070TAK-070Phase 1 ClinicalTakeda Pharmaceutical Co Ltd
Alzheimer Disease
Details